drugset / Trial / NCT01012752

A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts

NCT01012752 ↗

Phase 3 Unknown 150 enrolled Roxall
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is performed to evaluate the safety and clinical efficacy of subcutaneous specific immunotherapy in patients suffering from seasonal allergic rhinitis/rhinoconjunctivitis.

Timeline

Start
2016-10
Primary completion
2017-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator modified allergen extract Unknown — Subcutaneous